ACS Medicinal Chemistry Letters
Letter
activity of potent and orally available G protein-coupled receptor 40
agonists. J. Med. Chem. 2011, 54, 1365−1378.
tolerance test; LE, ligand efficiency; LLE, ligand lipophilicity
efficiency; OGTT, oral glucose tolerance test
(16) Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann,
M.; Schroder, R.; Hudson, B. D.; Milligan, G.; Cawthorne, M. A.;
Kostenis, E.; Kassack, M. U.; Ulven, T. Free fatty acid receptor 1
(FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophi-
licity and improves ADME properties. J. Med. Chem. 2012, 55, 6624−
6628.
REFERENCES
■
(1) Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.;
Chambers, J. K.; Eilert, M. M.; Ellis, C.; Elshourbagy, N. A.; Goetz, A.
S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R.; Shabon, U.; Spinage,
L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D.
M.; Wilson, S.; Muir, A. I. The orphan G protein-coupled receptor
GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem.
2003, 278, 11303−11311.
(17) Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a
useful metric for lead selection. Drug Discovery Today 2004, 9, 430−
431.
(18) Leeson, P. D.; Springthorpe, B. The influence of drug-like
concepts on decision-making in medicinal chemistry. Nat. Rev. Drug
Discovery 2007, 6, 881−890.
(19) Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Merten, N.;
Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.;
Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R. K.; Kristiansen,
K.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Ulven, T. Structure−
activity study of dihydrocinnamic acids and discovery of the potent
FFA1 (GPR40) agonist TUG-469. ACS Med. Chem. Lett. 2010, 1,
345−349.
(20) Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.;
Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.;
Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame,
A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: a
potent, selective, and orally bioavailable GPR40 agonist. ACS Med.
Chem. Lett. 2010, 1, 290−294.
(2) Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.;
Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka,
H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.;
Matsumura, F.; Noguchi, Y.; Shinobara, T.; Hinuma, S.; Fujisawa, Y.;
Fujino, M. Free fatty acids regulate insulin secretion from pancreatic
beta cells through GPR40. Nature 2003, 422, 173−176.
(3) Kotarsky, K.; Nilsson, N. E.; Flodgren, E.; Owman, C.; Olde, B. A
human cell surface receptor activated by free fatty acids and
thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 2003, 301,
406−410.
(4) Medina, J. C.; Houze, J. B. GPR40 (FFAR1) modulators. Annu.
Rep. Med. Chem. 2008, 43, 75−85.
(5) Holliday, N. D.; Watson, S. J.; Brown, A. J. Drug discovery
opportunities and challenges at G protein coupled receptors for long
chain free fatty acids. Front. Endocrinol. 2011, 2, 112.
(6) Blad, C. C.; Tang, C.; Offermanns, S. G protein-coupled
receptors for energy metabolites as new therapeutic targets. Nat. Rev.
Drug Discovery 2012, 11, 603−619.
(7) Burant, C. F.; Viswanathan, P.; Marcinak, J.; Cao, C.; Vakilynejad,
M.; Xie, B.; Leifke, E. TAK-875 versus placebo or glimepiride in type 2
diabetes mellitus: a phase 2, randomised, double-blind, placebo-
controlled trial. Lancet 2012, 379, 1403−1411.
(8) Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen,
K. K.; Hamacher, A.; Spinrath, A.; Bond, A. D.; Drewke, C.; Ullrich, S.;
Kassack, M. U.; Kostenis, E.; Ulven, T. Discovery of potent and
selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a
potential target for the treatment of type II diabetes. J. Med. Chem.
2008, 51, 7061−7064.
(9) Christiansen, E.; Urban, C.; Grundmann, M.; Due-Hansen, M. E.;
Hagesaether, E.; Schmidt, J.; Pardo, L.; Ullrich, S.; Kostenis, E.;
Kassack, M. U.; Ulven, T. Identification of a potent and selective free
fatty acid receptor 1 (FFA1/GPR40) agonist with favorable
physicochemical and in vitro ADME properties. J. Med. Chem. 2011,
54, 6691−6703.
(10) Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann,
M.; Schmidt, J.; Hansen, S. V. F.; Hudson, B. D.; Zaibi, M.; Markussen,
S. B.; Hagesaether, E.; Milligan, G.; Cawthorne, M. A.; Kostenis, E.;
Kassack, M. U.; Ulven, T. Discovery of a potent and selective free fatty
acid receptor 1 agonist with low lipophilicity and high oral
bioavailability. J. Med. Chem. 2013, 56, 982−992.
(11) Satoh, T.; Nanba, K.; Suzuki, S. Reduction of organic
compounds with NaBH4-transition metal salt systems 0.4. Selective
hydrogenation of olefines in unsaturated esters. Chem. Pharm. Bull.
1971, 19, 817−820.
(12) Christiansen, E.; Due-Hansen, M. E.; Ulven, T. A rapid and
efficient Sonogashira protocol and improved synthesis of free fatty acid
1 (FFA1) receptor agonists. J. Org. Chem. 2010, 75, 1301−1304.
(13) It was recently decided by IUPHAR to recommend the name
FFA4 for the receptor previously known as GPR120 (http://www.
(14) Shimpukade, B.; Hudson, B. D.; Hovgaard, C. K.; Milligan, G.;
Ulven, T. Discovery of a potent and selective GPR120 agonist. J. Med.
Chem. 2012, 55, 4511−4515.
(15) Sasaki, S.; Kitamura, S.; Negoro, N.; Suzuki, M.; Tsujihata, Y.;
Suzuki, N.; Santou, T.; Kanzaki, N.; Harada, M.; Tanaka, Y.;
Kobayashi, M.; Tada, N.; Funami, M.; Tanaka, T.; Yamamoto, Y.;
Fukatsu, K.; Yasuma, T.; Momose, Y. Design, synthesis, and biological
E
dx.doi.org/10.1021/ml4000673 | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX